Approval for extension of the rhbmp-2 drug substance expiration date from 60 to 72 months using the approved expiration date modification protocol. the device, as modified, will be marketed under the trade name infuse bone graft/lt-cage lumbar tapered fusion devices and is indicated for the following:  spinal fusion procedures in skeletally mature patients with degenerative disc disease (ddd) at one level from l4-s1. ddd is defined as discogenic back pain with degeneration of the disc confirmed by patient history, function deficit and/or neurological deficit and radiographic studies. these ddd patients may also have up to grade i spondylolisthesis at the involved level. infuse bone graft/lt-cage devices are to be implanted via an open anterior or a laparoscopic approach. patients receiving the infuse bone graft/ lt-cage lumbar tapered fusion device should have had at least six months of nonoperative treatment prior to treatment with the infuse bone graft/lt-cage device.